Toll-like receptor agonists as adjuvants for inactivated porcine reproductive and respiratory syndrome virus (PRRSV) vaccine

Show simple item record

dc.contributor.author Vreman, Sandra
dc.contributor.author McCaffrey, Joanne
dc.contributor.author Popma-de Graaf, Ditta J.
dc.contributor.author Nauwynck, Hans
dc.contributor.author Savelkoul, Huub F. J.
dc.contributor.author Moore, Anne C.
dc.contributor.author Rebel, Johanna M. J.
dc.contributor.author Stockhofe-Zurwieden, Norbert
dc.date.accessioned 2019-09-17T14:47:10Z
dc.date.available 2019-09-17T14:47:10Z
dc.date.issued 2019-04-30
dc.identifier.citation Vreman, S., McCaffrey, J., Popma-de Graaf, D. J., Nauwynck, H., Savelkoul, H. F. J., Moore, A. C., Rebel, J. M. J. and Stockhofe-Zurwieden, N. (2019) 'Toll-like receptor agonists as adjuvants for inactivated porcine reproductive and respiratory syndrome virus (PRRSV) vaccine', Veterinary Immunology and Immunopathology, 212, pp. 27-37. (10pp.) DOI: 10.1016/j.vetimm.2019.04.008 en
dc.identifier.volume 212 en
dc.identifier.startpage 27 en
dc.identifier.endpage 37 en
dc.identifier.issn 0165-2427
dc.identifier.uri http://hdl.handle.net/10468/8549
dc.identifier.doi 10.1016/j.vetimm.2019.04.008 en
dc.description.abstract Toll-like receptor (TLR) agonists can effectively stimulate antigen-presenting cells (APCs) and are anticipated to be promising adjuvants in combination with inactivated vaccines. In this study, the adjuvant potential of three different TLR-agonists were compared with an oil-in-water (O/W) adjuvant in combination with inactivated porcine reproductive and respiratory syndrome virus (iPRRSV) applied by different administration routes: intramuscular (i.m.) or into the skin using dissolving microneedle (DMN) patches. Pigs received a prime vaccination followed by a booster vaccination four weeks later. TLR1/2 (Pam3Cys), TLR7/8 (R848) or TLR9 (CpG ODN) agonists were used as adjuvant in combination with iPRRSV strain 07V063. O/W adjuvant (Montanide™) was used as reference control adjuvant and one group received a placebo vaccination containing diluent only. All animals received a homologous challenge with PRRSV three weeks after the booster vaccination. Antibody and IFN-γ production, serum cytokines and viremia were measured at several time-points after vaccination and/or challenge, and lung pathology at necropsy. Our results indicate that a TLR 1/2, 7/8 or 9 agonist as adjuvant with iPRRSV does not induce a detectable PRRSV-specific immune response, independent of the administration route. However, the i.m. TLR9 agonist group showed reduction of viremia upon challenge compared to the non-vaccinated animals, supported by a non-antigen-specific IFN-γ level after booster vaccination and an anamnestic antibody response after challenge. Montanide™-adjuvanted iPRRSV induced antigen-specific immunity after booster combined with reduction of vireamia. Skin application of TLR7/8 agonist, but not the other agonists, induced a local skin reaction. Further research is needed to explore the potential of TLR agonists as adjuvants for inactivated porcine vaccines with a preference for TLR9 agonists. en
dc.format.mimetype application/pdf en
dc.language.iso en en
dc.publisher Elsevier en
dc.relation.uri https://www.sciencedirect.com/science/article/pii/S0165242719300406?via%3Dihub
dc.rights ©2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND licence (http://creativecommons.org/licences/BY-NY-ND/4.0/). en
dc.rights.uri http://creativecommons.org/licences/BY-NY-ND/4.0/ en
dc.subject PRRSV en
dc.subject Vaccine en
dc.subject Adjuvant en
dc.subject Toll-like receptor agonist en
dc.subject Skin vaccination en
dc.title Toll-like receptor agonists as adjuvants for inactivated porcine reproductive and respiratory syndrome virus (PRRSV) vaccine en
dc.type Article (peer-reviewed) en
dc.internal.authorcontactother Anne Moore, School of Pharmacy, University College Cork, Cork, Ireland. +353-21-490-3000 Email:Anne.Moore@ucc.ie en
dc.internal.availability Full text available en
dc.description.version Published Version en
dc.contributor.funder Horizon 2020 en
dc.description.status Peer reviewed en
dc.identifier.journaltitle Veterinary Immunology and Immunopathology en
dc.internal.IRISemailaddress Anne.Moore@ucc.ie en
dc.relation.project info:eu-repo/grantAgreement/EC/H2020::RIA/633184/EU/Strengthening Animal Production and Health through the Immune Response/SAPHIR en
dc.identifier.eissn 1873-2534


Files in this item

This item appears in the following Collection(s)

Show simple item record

©2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND licence (http://creativecommons.org/licences/BY-NY-ND/4.0/). Except where otherwise noted, this item's license is described as ©2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND licence (http://creativecommons.org/licences/BY-NY-ND/4.0/).
This website uses cookies. By using this website, you consent to the use of cookies in accordance with the UCC Privacy and Cookies Statement. For more information about cookies and how you can disable them, visit our Privacy and Cookies statement